LY3526318

DRUG7 trials

Sponsors

Eli Lilly and Company

Conditions

Chronic Low-back PainDiabetic Peripheral Neuropathic PainHealthyOsteo Arthritis KneeOsteoarthritis

Phase 1

A Study of LY3526318 in Healthy Participants

TerminatedNCT03977974

Eli Lilly and CompanyHealthy

Start: 2019-06-21End: 2020-03-05Updated: 2025-09-12

A Study of LY3526318 in Healthy Women

CompletedNCT04183283

Eli Lilly and CompanyHealthy

Start: 2019-12-12End: 2020-03-06Updated: 2025-10-06

A Safety Study of LY3526318 in Healthy Participants

CompletedNCT04682119

Eli Lilly and CompanyHealthy

Start: 2020-12-29End: 2021-04-21Updated: 2025-09-10

A Study of LY3526318 in Healthy Male Japanese Participants

WithdrawnNCT05580250

Eli Lilly and CompanyHealthy

Start: 2022-11-01End: 2022-12-01Updated: 2026-09-08

Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

CompletedNCT05080660

Eli Lilly and CompanyOsteoarthritis, Osteo Arthritis Knee

Start: 2021-10-12End: 2022-06-06Updated: 2024-07-17

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain

CompletedNCT05086289

Eli Lilly and CompanyChronic Low-back Pain

Start: 2021-10-25End: 2022-06-17Updated: 2023-10-05

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

CompletedNCT05177094

Eli Lilly and CompanyDiabetic Peripheral Neuropathic Pain

Start: 2022-01-26End: 2022-10-13Updated: 2023-11-22